Metabolic health
Next-generation incretin and mitochondrial programmes targeting the biology behind obesity and type 2 diabetes.
Innovative medicines company
Innovative medicines for the diseases that define a life
We turn deep biology into treatments people can actually get. From first molecule to last mile, our work is measured in patients reached.
22
Medicines in clinical development
48M
Patients reached each year
6,400
Colleagues across 34 countries
21%
Of revenue reinvested in R&D
Our science
Biology first. Chemistry second. Patients throughout.
Our discovery engine pairs human genetics with protein engineering, so every candidate starts from a validated target rather than a promising screen. It is a slower start and a far higher success rate.
- Human-genetics-anchored target selection
- In-house peptide and protein engineering
- Trials designed with patient advocacy groups from day one
Three therapy areas where we can change the standard of care
See products
Rare disease
Precision protein therapies for inherited disorders where fewer than one in ten patients has a treatment today.
Immunology
Selective modulators designed to calm chronic inflammation without compromising immune defence.
Pipeline highlights
Selected clinical-stage programmes as of the most recent quarterly update.
EXX-114
Obesity
Phase 3
EXX-207
Type 2 diabetes
Phase 2b
EXX-330
Fabry disease
Phase 2
EXX-418
Lupus nephritis
Phase 1
Access
A medicine only works if it reaches someone
We price for sustainability, not for maximum extraction, and we run access programmes in 42 low- and middle-income countries. By 2030, we've committed to reaching six million more people with chronic disease care.
Read our access commitments
About Exxopharm
Founded in 2009 around a single question — why do so many validated targets never become medicines — Exxopharm now runs research sites in Copenhagen, Basel and Boston, and manufactures at scale in Kalundborg.
We are majority-owned by a foundation. That structure lets us fund decade-long science, hold our nerve through hard data, and keep patients ahead of quarters.
More about Exxopharm